Several abstracts are listed on a post in the IV MB. Moat is very early stage, it looks like the Bayer drug will be the only potential significant human clinical data from this meeting. There's an oral presentation on April 9.
Regarding the Cramer post, I did not hear him say anything negative about IMGN, he said he had Junius on th eshow, they have a lot going on and he had endorsed it at lower prices, it was not a screaming buy, not an avoid and buy something else, more neutral because he was featuring other stocks. Just passing through, sure.
wow, some bad early morning typing...the abstracts are early stage, animals, animal models, etc.
Here's some info pasted from a Bayer press release posted April 1:
Two of these compounds are BAY 87-2243, an inhibitor of hypoxia-inducible HIF-1? activation, and MT112/BAY 2010112, a BiTE® antibody, being developed in partnership with Micromet, Inc. Data will also be presented on two compounds, BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC) developed in collaboration with ImmunoGen Inc., and BAY 79-4620, a CA9-targeted ADC developed in collaboration with Seattle Genetics, Inc. These compounds are being developed to target antigens, mesothelin and carbonic anhydrase 9 (CA9), both of which are selectively expressed on certain tumors.
• Identification of BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models
o Abstract 1754, Targeting Cell Surface Proteins/Apoptosis Poster Session
o Monday, April 4, 2011, 8:00 a.m.-12:00 p.m., Exhibit Hall A4-C